Researchers from Memorial Sloan Kettering Cancer Center have discovered subclonal co-mutations and immunophenotypic profiles that can distinguish individual cells indicative of future AML relapse from others present after treatment using Mission Bio Inc.’s Tapestri Single-cell Multi-omics Measurable Residual Disease assay.
From left to right: Vittoria Bocchi, Melissa Yao, Julia Brunner, Tzippora Chwat-EdelsteinVittoria Bocchi, Julia Brunner, Melissa Yao, and Tzippora Chwat-Edelstein, four Sloan Kettering Institute researchers, were named 2024 Marie-Josée Kravis Women in Science Endeavor, or Kravis WiSE, fellowship grant recipients.
